🔴 Clearpoint Neuro is trading 12.3% down in pre-market after Q2 earnings miss and revised 2026 guidance

Clearpoint Neuro is trading 12.3% down now at $14.00 after renewed attention to its second-quarter results and outlook.

• Q2 revenue was $10.9 million, while earnings missed expectations; 2026 revenue guidance was revised to $48 million–$52 million.
• Coverage updated on August 20 linked the earlier results to a 15.47% after-hours decline; no fresh overnight company announcement was found.
• Broader healthcare strength does not explain the opposite-direction move.